Cargando…
RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo
Pancreatic neuroendocrine tumors (pNETs) are difficult-to-treat neoplasms whose incidence is rising. Greater understanding of pNET pathogenesis is needed to identify new biomarkers and targets for improved therapy. RABL6A, a novel oncogenic GTPase, is highly expressed in patient pNETs and required f...
Autores principales: | Maharjan, Chandra K., Umesalma, Shaikamjad, Kaemmer, Courtney A., Muniz, Viviane P., Bauchle, Casey, Mott, Sarah L., Zamba, K. D., Breheny, Patrick, Leidinger, Mariah R., Darbro, Benjamin W., Stephens, Samuel B., Meyerholz, David K., Quelle, Dawn E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228095/ https://www.ncbi.nlm.nih.gov/pubmed/34199469 http://dx.doi.org/10.3390/biomedicines9060633 |
Ejemplares similares
-
RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner
por: Kohlmeyer, Jordan L., et al.
Publicado: (2021) -
Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis
por: Kaemmer, Courtney A., et al.
Publicado: (2021) -
Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo
por: Kohlmeyer, Jordan L, et al.
Publicado: (2022) -
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas
por: Desai, Chandni, et al.
Publicado: (2021) -
Combination therapies for MPNSTs targeting RABL6A-RB1 signaling
por: Kohlmeyer, Jordan L., et al.
Publicado: (2021)